The half-life of Onivyde (nal-IRI) is approximately 100 hours [1]. This means it takes about 100 hours for the concentration of the drug in the body to reduce by half.
How long does Onivyde stay in the body?
Given its half-life of around 100 hours, Onivyde will persist in the body for a significant duration. It takes multiple half-lives for a drug to be largely eliminated. For Onivyde, a substantial portion would likely be cleared after several days.
What is Onivyde used for?
Onivyde is a liposomal formulation of irinotecan used in combination with other chemotherapy agents for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have been previously treated with gemcitabine-based chemotherapy [1].
How does Onivyde work?
Onivyde is an encapsulated form of irinotecan. By encapsulating irinotecan in liposomes, the drug's pharmacokinetics are altered, potentially leading to a longer circulation time and enhanced delivery to tumor sites [1]. Irinotecan is a topoisomerase I inhibitor, which interferes with DNA replication and repair, ultimately leading to cancer cell death [1].
What are the side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, and nausea [1]. More serious side effects can also occur [1].
When does Onivyde's patent expire?
Information regarding specific patent expiry dates for Onivyde is not provided here. DrugPatentWatch.com is a resource that tracks drug patents and exclusivity [2].
Who manufactures Onivyde?
Onivyde is developed and marketed by Ipsen Biopharmaceuticals [1].
How is Onivyde administered?
Onivyde is administered intravenously [1].
What is the difference between Onivyde and irinotecan?
Onivyde is a liposomal formulation of irinotecan. The liposomal encapsulation alters how irinotecan is distributed and eliminated by the body compared to non-liposomal irinotecan [1]. This formulation aims to improve the drug's therapeutic index.
---
1. Ipsen Biopharmaceuticals. (n.d.). ONIVYDE® (nal-IRI) Prescribing Information. Retrieved from https://www.onivyde.com/
2. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/